


# Supplementary Materials: Biomimetic Red Blood Cell Membranes-Mediated Nanodrugs Loading Ursolic Acid for Targeting NSCLC Therapy


Ting Wu, Dan Yan, Wenjun Hou, Hui Jiang, Min Wu, Yanling Wang, Gang Chen, Chunming Tang, Yijun Wang and Hua Xu

**Table S1.** The size and zeta-potential of UaNPs (a) and UMNPs (b).


| Samples | Size(nm)    | Zeta-potential(mV) |
|---------|-------------|--------------------|
| UaNPs   | 100.5±1.05% | -17.23±0.16%       |
| UMNPs   | 112.0±2.96% | -24.47±0.52%       |




**Figure S1.** The size of UaNPs (a) and UMNPs (b).





**Figure S2.** Original western blots picture of CD47.



**Figure S3.** Original western blots picture of PARP LC3 P62.



**Figure S4.** TIR of UaNP and UMNPs. Differences were considered significant when  $**p < 0.01$ .



**Figure S5.** Hemolytic risk assessment of UA, UaNP, UMNPs. Differences were considered significant when  $****p < 0.0001$ , while there is no significant when  $p > 0.05$  which means ns.